Figure 2.

Kaplan–Meier curves depicting the cumulative event rate (safety population): (A) major adverse cardiovascular event, (B) fatal and non-fatal myocardial infarction, and (C) fatal and non-fatal stroke. *The hazard ratio and 95% confidence interval are from a Cox model with treatment and study ID as factors. ^†The major adverse cardiovascular event count includes both non treatment-emergent adverse events and treatment-emergent adverse events. In the placebo arm, three non treatment-emergent adverse events occurred on or after the Screening date, within seven days of first dose, but prior to first dose. To avoid a ‘negative time-to-first event’ for these three patients, these events were not included in the time-to-first event analysis; instead, these patients were treated as missing.